Clinical - ABL SA : ABL SA

Read more

EMRs - Registries - Integration tool

Read more

Clinical solutions

Discover our solutions

Clinical applications

Discover our applications

WHO algorithm v2021-06 for Tuberculosis resistance now available!

Jul 26, 2022

We are pleased to announce the immediate availability of the WHO Catalog of Mutations (version 2021-06) in BacterioChek-TB, intended to be used for Mycobacterium tuberculosis drug resistance assessement.
ABL received CE-IVD Mark for its “UltraGene™ Assay SARS-CoV-2 PrimeChek™”

Jun 28, 2022

The UltraGene™ Assay SARS-CoV-2 PrimeChek™ is a CE-IVD marked real-time RT-PCR test intended for the qualitative detection of RNA from the SARS-CoV-2 in upper respiratory specimens from individuals suspected of COVID-19 by their healthcare provider.
New Distribution Partners in Georgia & Paraguay !

Jun 23, 2022

This week we are proud to have two new Distribution Partners on our side : – ELTA 90 Medical Genetics in Georgia – Infotec in Paraguay Both agreements will cover all ABL’s Diagnostics line of products, including the DeepChek® Assays and Softwares.
Read more

SIGNATURE D’UN TRAITE DE FUSION

Jun 14, 2022

Le Conseil d’administration de la société ABL Diagnostics (la « Société »), réuni le 13 juin 2022, a approuvé le projet de fusion-absorption aux termes duquel il est prévu que la Société absorbe la société Advanced Biological Laboratories Fedialis (« ABL France »), chacune des deux sociétés étant co…
Read more
New Distribution Partnership in Ethiopia & Bolivia

Jun 09, 2022

We are pleased to announce that we entered into an exclusive distribution agreement 🤝 of ABL’s Diagnostics line of products, including the DeepChek® Assays 🔬and software: – With Retina Pharmaceuticals in Ethiopia; – With Bionova in Bolivia !
Read more
DeepChek® Assay 13-Plex KB Drug Susceptibility Testing is now CE-IVD marked

Jun 06, 2022

We are pleased to announce that our DeepChek® Assay 13-Plex KB Drug Susceptibility Testing, intended to be used for Tuberculosis Drug Resistance assessment through NGS sequencing, is now CE-IVD marked !
Read more

Presentation of the DeepChek-HIV Whole Genome Assay @ECCMID 2022

Apr 25, 2022

We are pleased to announce a new poster presentation entitled “Evaluation of a commercial assay whole genome HIV-1 using next-generation sequencing” at ECCMID 2022. Link to the poster presentation. Please feel free to contact us to get more information.
Read more
ETABLISSEMENTS FAUVET GIREL – RESULTATS ANNUELS 2021

Feb 09, 2022

ETABLISSEMENTS FAUVET GIREL (FR0000063034 – FAUV – Euronext Paris) publie ses résultats annuels au titre de l’exercice clos le 31 décembre 2021, arrêtés par le Conseil d’administration du 8 février 2022. Les comptes ont été audités par le commissaire aux comptes dont le rapport de certification est…
Read more
ABL Announces Distribution Agreement with Geneplus Co Ltd in Thailand

Feb 07, 2022

Advanced Biological Laboratories (ABL) S.A. and Geneplus Co Ltd are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Thailand. See current channel partners.
Read more